News

A Phase 2 clinical trial testing the efficacy and safety of three investigational therapies — filgotinib, GS-9876, and tirabrutinib  — in adults with active Sjögren’s syndrome is recruiting participants. The study (NCT03100942) is being conducted by Gilead Sciences, in collaboration with Galapagos. It is expected to enroll 140 patients with active Sjögren’s…

This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into the 7,000 known rare diseases that afflict at least 30 million Americans. The campaign kicks off Feb. 1 and culminates with Rare Disease Day on Feb. 28. Organized by…

Patients with an underlying rheumatic disease, including Sjogren’s syndrome, are not at higher risk for adverse effects when receiving cancer immunotherapies – called immune checkpoint inhibitors – than the rest of the population, according to the results of a Mayo Clinic study. The report, “Cancer immunotherapy in patients…

Women with Sjögren syndrome show particularly high levels of hearing loss and language recognition impairments compared to healthy women or those with rheumatoid arthritis (RA), study reports. The research, “Early hearing loss detection in rheumatoid arthritis and primary Sjögren syndrome using extended high frequency audiometry,” was published in the…